Mirvetuximab Soravtansine News
Mirvetuximab Soravtansine currently has 0 news articles, with 20 predicted indications.
This page combines the AI-predicted indications for Mirvetuximab Soravtansine with the latest health news. Indications highlighted in orange have recent news coverage.
Drug Information
- Original indication: Elahere as monotherapy is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant high grade serous epithelial ovarian, fallopian tube, or primary...
- Evidence level: L5
- Predicted indications (20):
- antithrombin deficiency type 2 (98.0%)
- heparin cofactor 2 deficiency (97.8%)
- factor 5 excess with spontaneous thrombosis (97.8%)
- candidiasis (97.7%)
- plasma cell myeloma (97.6%)
- indolent plasma cell myeloma (97.4%)
- tinea corporis (96.8%)
- thrombophilia (96.7%)
- uterine polyp (96.6%)
- pediatric systemic lupus erythematosus (96.5%)
- polyp of vocal cord (96.5%)
- polyp of middle ear (96.5%)
- polyp of frontal sinus (96.4%)
- polyp of external auditory canal (96.4%)
- polyp of ureter (96.4%)
- polyp of vulva (96.4%)
- fibroepithelial polyp (96.4%)
- neoplastic polyp (96.3%)
- epulis (96.3%)
- mantle cell lymphoma (96.1%)
Related News (0)
No related news yet. When news mentions this drug, it will be collected and shown here automatically.
Disclaimer: The news on this page is collected automatically and is for research reference only; it does not constitute medical advice.